A detailed history of Nordea Investment Management Ab transactions in Dynavax Technologies Corp stock. As of the latest transaction made, Nordea Investment Management Ab holds 777,816 shares of DVAX stock, worth $10.2 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
777,816
Previous 545,126 42.69%
Holding current value
$10.2 Million
Previous $6.07 Million 63.57%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 06, 2025

BUY
$10.28 - $13.66 $2.39 Million - $3.18 Million
232,690 Added 42.69%
777,816 $9.93 Million
Q3 2024

Nov 05, 2024

BUY
$10.05 - $11.61 $2.21 Million - $2.56 Million
220,298 Added 67.82%
545,126 $6.07 Million
Q2 2024

Aug 08, 2024

SELL
$10.73 - $12.58 $739,865 - $867,428
-68,953 Reduced 17.51%
324,828 $3.65 Million
Q1 2024

May 02, 2024

BUY
$11.7 - $14.98 $862,067 - $1.1 Million
73,681 Added 23.02%
393,781 $4.89 Million
Q4 2023

Jan 10, 2024

SELL
$13.09 - $14.98 $94,967 - $108,679
-7,255 Reduced 2.22%
320,100 $4.47 Million
Q3 2023

Nov 13, 2023

BUY
$12.64 - $14.99 $26,329 - $31,224
2,083 Added 0.64%
327,355 $4.84 Million
Q2 2023

Jul 07, 2023

BUY
$9.85 - $13.17 $590,182 - $789,106
59,917 Added 22.58%
325,272 $4.2 Million
Q1 2023

Apr 19, 2023

SELL
$9.44 - $11.88 $36,646 - $46,118
-3,882 Reduced 1.44%
265,355 $2.6 Million
Q4 2022

Feb 08, 2023

BUY
$10.27 - $13.29 $1.11 Million - $1.43 Million
107,846 Added 66.82%
269,237 $2.86 Million
Q3 2022

Oct 19, 2022

BUY
$9.93 - $17.44 $19,343 - $33,973
1,948 Added 1.22%
161,391 $1.7 Million
Q2 2022

Aug 09, 2022

BUY
$7.45 - $12.83 $90,957 - $156,641
12,209 Added 8.29%
159,443 $1.96 Million
Q1 2022

Apr 11, 2022

BUY
$9.75 - $14.44 $1.25 Million - $1.85 Million
128,230 Added 674.75%
147,234 $1.7 Million
Q4 2021

Jan 20, 2022

BUY
$13.17 - $20.94 $250,282 - $397,943
19,004 New
19,004 $270,000

Others Institutions Holding DVAX

About DYNAVAX TECHNOLOGIES CORP


  • Ticker DVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 126,474,000
  • Market Cap $1.65B
  • Description
  • Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...
More about DVAX
Track This Portfolio

Track Nordea Investment Management Ab Portfolio

Follow Nordea Investment Management Ab and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nordea Investment Management Ab, based on Form 13F filings with the SEC.

News

Stay updated on Nordea Investment Management Ab with notifications on news.